DME in 2016: A Review of Treatment Guidelines and the Role of Early Appropriate Therapy

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

Charles C. Wykoff, MD, PhD, moderator Retina Consultants of Houston, Blanton Eye Institute Houston, Texas

Caroline R. Baumal, MD New England Eye Center Boston, Massachusetts

David Eichenbaum, MD Retina Vitreous Associates of Florida Tampa, Florida

Chirag P. Shah, MD, MPH Ophthalmic Consultants of Boston Boston, Massachusetts

It is the policy of Evolve Medical Education LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve Medical

Education LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Charles C. Wykoff, MD, PhD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Alimera Sciences; Allergan; Bayer Pharmaceuticals; Clearside Biomedical; DORC International; Genentech; ONL Therapeutics; Regeneron Pharmaceuticals; and ThromboGenics NV. Grant/Research Support: Acucela; Alcon; Allegro Ophthalmics LLC; Allergan; Ampio Pharmaceuticals; Apellis Pharmaceuticals; Clearside Biomedical; Genentech; Iconic Therapeutics; Ophthotech Corporation; pSivida Corp.; Regeneron Pharmaceuticals; Roche Pharma; Santen Pharmaceutical Co., Ltd.; ThromboGenics NV; and XOMA Ltd.

Caroline R. Baumal, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Advisory Board/Speaker’s Bureau: Allergan; and Genentech.

David Eichenbaum, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Alimera Sciences; Allergan; Genentech; Ophthotech Corporation; and Regeneron Pharmaceuticals. Grant/Research Support: Alcon; Alimera Sciences; Allergan; Genentech; Ophthotech Corporation; and River Vision. Stock/Shareholder: Hemera Biosciences; and US Retina.

Chirag P. Shah, MD, MPH, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research Support: Genentech; and Regeneron Pharmaceuticals.

Cheryl Cavanaugh, MS, director of operations, Evolve Medical Education LLC; Emily Feinman, administrator, New Retina MD and Retina Today; Michelle Dalton, writer; and Melanie Lawler, PhD, reviewer, have no financial relationships with commercial interests.